Portela-Ortiz JM, Mille-Loera JE, Aréchiga-Ornelas G

Idioma: Español
Referencias bibliográficas: 11
Paginas: 95-97
Archivo PDF: 480.72 Kb.

FRAGMENTO

El desarrollo de nuevos anticoagulantes es un campo de investigación actual, que trata de superar los problemas asociados al uso de coumadínicos, y de las heparinas fraccionadas. El objetivo es contar con fármacos, que de preferencia por vía oral, tengan un mayor rango de seguridad, menor interacción con otros fármacos, menor incidencia de sangrados graves, no produzcan el síndrome de HIT (síndrome de trombocitopenia y trombosis asociado al uso de heparinas), y puedan ser administrados de preferencia con dosis única diaria.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Geerts WH, Bergquist D, Pineo GF. Prevention of venous thromboembolism: American College of Chest Physicians evidence based clinical practice guidelines. Chest 2008;133:381-453.

2. Lassen MR, Ageno W, Borris LC. Rivaroxaban for thromboprophylaxis after total knee arthroplasty. N Eng J Med 2008;358:2776-2785.

3. Anderson FA, Wheeler HB, Goldberg RJ. A population based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: The Worcester DVT Study. Arch Inter Med 1991;151:933-938.

4. Wong PC, Crain EJ, Xin B. Apixaban, an oral, direct and selective factor Xa inhibitor: In vitro antithrombotic and antihemostatic studies. J Thromb Haemost 2007;6:820-829.

5. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ. Venous thromboembolism risk and prophylaxis in the acute hospital care setting: A multinational cross section study. Lancet 2008;371:387-394.

6. Matheson AJ, Goa KL. Desirudin: A review of its use in the management of thrombotic disorders. Drugs 2000;60:679-700.

7. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development. Clin Pharmacokinet 2009;48:1-22.

8. Walenga JM, Prechel M, Jeske WP. Rivaroxaban an oral direct factor Xa inhibitor has potential for the management of patients with heparin induced thrombocytopenia. Br J Haematol 2008;142:92-99.

9. Levy JH, Key NS, Azran MS. Novel oral anticoagulants: Implications in the perioperative setting. Anesthesiology 2010;113:726-745.

10. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Samama ChM. Regional anaesthesia and antithrombotic agents: Recommendations of the European Society of Anaesthesiology. Eur J Anaesth 2010;27:999-1015.

11. Squizzato A, Romualdi E, Dentali F, Ageno W. The new oral anticoagulants, do they change the benefit vs risk for thromboprophylaxis in association to ambulatory surgery? Curr Op Anesth 2010;23: 722-725.